slide1 n.
Skip this Video
Loading SlideShow in 5 Seconds..
NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB PowerPoint Presentation
Download Presentation
NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB

play fullscreen
1 / 23
Download Presentation

NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB - PowerPoint PPT Presentation

vern
117 Views
Download Presentation

NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB

- - - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript

    1. NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB Pr Alain Ravaud. Medical Oncology. University Hospital- Bordeaux- France

    2. BEVACIZUMAB Humanized VEGF mAb 93% human Dose : 3mg/kg : Pk similar to optimally effective dose in preclinical mouse model 10 mg/kg max.dose in phase I with no MTD

    4. BEVACIZUMAB. > 1st LINE

    6. BEVACIZUMAB

    7. BEVACIZUMAB 1st targeted drug validating a modification of the natural history of MRCC Validation of angiogenesis as a major event in MRCC natural history as least by the VEGF pathway Manageable safety profile ? go to 1st line ? Explore combination for VEGF or other pathway

    8. BEVACIZUMAB. 1ST LINE

    9. BEVACIZUMAB. 1ST LINE

    10. BEVACIZUMAB. 1ST LINE

    11. BEVACIZUMAB. 1ST LINE

    13. AVOREN A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a versus interferon alfa-2a and placebo as first-line treatment administered to patients with MRCC

    18. PFS AND MOTZERS RISK GROUP

    22. BEVACIZUMAB + OTHERS Bevacizumab + anti VEGF pathway + Sunitinib : phase I ? II + Sorafenib : phase I ? II Bevacizumab + mTOR inhition + CCI : phase I + RAD 001 : phase I

    23. BEVACIZUMAB Highly effective in MRCC Effective as 1st line or following immunotherapy Low level of complete response Unknown : Bevacizumab + INF or Bevacizumab alone ? New option in 1st line in MRCC with Sunitinib as the standard